Companies
/
Prime Medicine
Healthtech
Prime Medicine is a publicly traded, Cambridge, Massachusetts-based biotechnology company developing gene editing therapies using "prime editing," a more precise gene editing technique than standard CRISPR.
Create an account to view live offerings, pricing, and market activity.
Sign in to view offerings and live market activity.
Prime Medicine was founded in 2019 by David Liu, Andrew Anzalone, and other scientists from the Broad Institute of MIT and Harvard, built around prime editing, a gene editing technology Liu's lab developed as a refinement of standard CRISPR-Cas9 gene editing, which typically works by cutting both strands of a DNA double helix at a targeted location, a process that, while powerful, can sometimes introduce unintended errors or genetic changes at the cut site as a cell's natural DNA repair machinery responds to the break. Prime editing instead uses a modified approach that can directly search for and replace a specific, targeted stretch of genetic code with a desired new sequence without fully cutting both DNA strands, an approach the company argues offers greater precision and a lower risk of unintended genetic changes compared to standard CRISPR-based gene editing. The company has argued that prime editing's improved precision could make it suitable for treating a substantially broader range of genetic diseases than standard CRISPR editing can safely address, including diseases caused by many different types of small genetic mutations, insertions, or deletions, since prime editing's more controlled, template-guided editing mechanism can, in principle, make a much wider variety of precise genetic corrections beyond the simpler "cut and disable" or larger deletion edits that standard CRISPR approaches are often best suited for. Prime Medicine has pursued a pipeline of potential gene editing therapies targeting various genetic diseases, including certain inherited disorders affecting the liver, eye, and other organ systems, working to translate its foundational prime editing technology into actual clinical-stage therapeutic candidates, a lengthy and capital-intensive process common across the broader gene editing therapeutics industry given the rigorous safety and efficacy testing required before any gene editing therapy can reach patients. The company completed an initial public offering in 2023. Prime Medicine has raised substantial funding from investors including F-Prime Capital and GV both prior to and following its public listing, positioning itself within the fast-evolving precision gene editing therapeutics industry alongside other companies pursuing CRISPR-based and other gene editing approaches, including Intellia Therapeutics and Editas Medicine.
FOR QUALIFIED INSTITUTIONAL AND ACCREDITED INVESTORS ONLY: Under federal securities laws, private market investments on this platform are available exclusively to Institutional and Accredited Investors. Verification of status required before investing. Private investments involve significant risks including illiquidity, potential loss of principal, and limited disclosure requirements. "Augment" refers to Augment Markets, Inc. and its affiliates. Augment Markets, Inc. is a technology company offering software and data services, not a bank or financial institution. Cash Accounts are provided by Modern Treasury Corp. financial institution partners and through Augment's technology. Augment does not act as a money services business, provide money transmission, or serve as a custodian of funds. Funds held in your Cash Account are not FDIC insured unless expressly disclosed. Full terms available in the Augment Cash Account Agreement. Brokerage services are offered through Augment Capital, LLC, an affiliated broker-dealer and member FINRA/SIPC. "Investment accounts" are not brokerage accounts and do not hold customer funds or securities. Investment advisory services are offered through Augment Advisors, LLC, an SEC-registered investment adviser. Registration with the SEC does not imply a certain level of skill or training. Neither Augment Advisors, LLC nor Augment Capital, LLC provide legal or tax advice; consult your attorney or tax professional regarding your specific situation. For additional information, please refer to Augment Advisors, LLC's Form ADV Part 2A (Firm Brochure) and FINRA BrokerCheck.
No news available for this company.
